A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor

The PI3K–AKT pathway is expected to be a therapeutic target for non-small cell lung cancer (NSCLC) treatment. We previously reported that a novel PI3K inhibitor iMDK suppressed NSCLC cells in vitro and in vivo without harming normal cells and mice. Unexpectedly, iMDK activated the MAPK pathway, incl...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Exp Cell Res
Päätekijät: Ishida, Naomasa, Fukazawa, Takuya, Maeda, Yutaka, Yamatsuji, Tomoki, Takaoka, Munenori, Haisa, Minoru, Yokota, Etsuko, Shigemitsu, Kaori, Morita, Ichiro, Kato, Katsuya, Matsumoto, Kenichi, Shimo, Tsuyoshi, Okui, Tatsuo, Bao, Xiao-Hong, Hao, Huifang, Grant, Shawn N., Takigawa, Nagio, Whitsett, Jeffrey A., Naomoto, Yoshio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485577/
https://ncbi.nlm.nih.gov/pubmed/25839409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yexcr.2015.03.019
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia